NCT06924073 Scale-up of an Evidence-based Adolescent Transition Package to Support Transitional Care Among Youth Living With HIV
| NCT ID | NCT06924073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Adolescent HIV Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,920 participants |
| Start Date | 2025-10-16 |
| Primary Completion | 2029-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,920 participants in total. It began in 2025-10-16 with a primary completion date of 2029-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ending the HIV epidemic for youth living with HIV will require implementation and optimization of evidence-based interventions that address barriers to treatment. The proposed implementation study will test a youth-led data-driven implementation strategy to scale-up an evidence-based Adolescent Transition Package (ATP) aimed at improving transition processes and post-transition clinical outcomes for youth living with HIV in Kenya. Clinics will be randomized to receive standard of care implementation through trainer of trainers or the youth-led data-driven implementation strategy alongside trainer of trainers. We will study whether the enhanced implementation strategy improves the number of youth who receive the ATP, the number of providers that initially chose to use the ATP, and the consistency with which the ATP is used over time. We will also evaluate the cost of the ATP and whether the ATP improves health outcomes among youth living with HIV, including viral suppression and retention in care. Healthcare workers at study sites will complete surveys, focus group discussions, interviews, and participate in continuous quality improvement processes. Youth will participate in surveys and focus groups, and have their routine medical records abstracted.
Eligibility Criteria
Inclusion Criteria: Healthcare providers * ≥18 years of age * Employed at one of the 32 facilities in the RCT * Provides HIV services to adolescents affiliated within their clinic Adolescents and youth living with HIV * Between 15-24 years of age (focus group discussions, surveys) or between 10-24 years of age (offered the intervention) * Receives HIV clinical care at one of the clinics included in the study * Attended clinic ≥1 time following intervention implementation Exclusion Criteria: Any individual who meets the following criteria will be excluded from participation in this study: \- Conditions that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study
Contact & Investigator
Kristin M Beima-Sofie, PhD, MPH
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT06924073 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, studying Adolescent HIV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06924073 currently recruiting?
Yes, NCT06924073 is actively recruiting participants. Contact the research team at beimak@uw.edu for enrollment information.
Where is the NCT06924073 trial being conducted?
This trial is being conducted at Awendo, Kenya, Awendo, Kenya, Gatundu, Kenya, Kiambu, Kenya and 11 additional locations.
Who is sponsoring the NCT06924073 clinical trial?
NCT06924073 is sponsored by University of Washington. The principal investigator is Kristin M Beima-Sofie, PhD, MPH at University of Washington. The trial plans to enroll 1,920 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.